U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07411599) titled 'Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")' on Feb. 09.
Brief Summary: To find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.
Study Start Date: July 29, 2026
Study Type: INTERVENTIONAL
Condition:
Colorectal Cancer
Peritoneal Metastases
Carcinomatosis
Intervention:
DRUG: Cyclo...